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P
 
OLYPEPTIDE
 
 growth factors (GFs)
 
1
 
 play a fundamen-
tal role during embryogenesis and regeneration
(e.g., wound healing) by stimulating proliferation
and differentiation of certain cell populations. Some GFs
can be responsible also for malignant transformation and
tumor growth (e.g., FGF-4: 
 
hst1 
 
oncogene). GF receptors
(GFRs) are generally known as plasma membrane pro-
teins which “send” signals to the nucleus principally via
the MAPK and the JAK-STAT pathways (Karin and
Hunter, 1995). However, in the past few years data were
accumulating to suggest that, surprisingly, nuclear target-
ing and action of GFs and GF receptors could occur as
well. This alternative or complementary signaling pathway
appears to be involved in the induction of cell prolifera-
tion. In addition, nuclear GF–GFR complexes may partici-
pate in the activation of cell line–specific genes as well.
Since by far the largest body of data has been published in
relation to FGF-1 and -2 (aFGF and bFGF), we have fo-
cused here on the nuclear role of these GFs.
 
Mitogenic Effect and Developmental Appearance of 
Nucleus-associated GFs
 
Similar to steroid and thyroid hormones, vitamin D3, and
retinoic acid, it appears that GFs may be present and func-
tion in cell nuclei. In different target cells, nuclear associa-
tion was shown for FGF, EGF, NGF, PDGF, insulin, etc.
(for reviews see Burwen and Jones, 1987; Jans, 1994; Pro-
chiantz and Theodore, 1995; Jans and Hassan, 1998; on
FGFs: Mason, 1994; M.K. Stachowiak et al., 1997). Al-
though the idea of nuclear GFs is more or less accepted,
the functional significance is generally debated based on
some reports. For example, activation of the Raf-MAPK
pathway was shown to be sufficient and necessary for
transduction of the aFGF mitogenic signal in BaF3 he-
matopoietic cells (Huang et al., 1995). Still, several data in-
dicate that nuclear localization of FGFs may be required
for the mitogenic effect in certain conditions in different
cell types.
The presence of radiolabeled, externally added aFGF in
the nuclear fraction appeared to correlate with stimulation
of DNA synthesis in a concentration-dependent manner in
NIH 3T3 cells (with a submaximal [
 
3
 
H]thymidine incorpo-
ration value at 10 ng/ml FGF-1). Correlation between nu-
clear association of aFGF and DNA synthesis was demon-
strated also in diphtheria toxin–resistant U2 Os Dr1 cells.
Although these cells lack aFGF receptors, they were able
to internalize aFGF via their cell surface toxin receptors, if
the GF was fused to the diphtheria toxin fragments. After
extracellular administration, the aFGF-toxin label was de-
tected in the nuclear fraction. At the same time, DNA syn-
thesis was found to rise about fourfold (at a fairly low, 5
ng/ml aFGF-toxin). However, no significant increase in
the number of cells was observed. Therefore, it appears
that although nuclear action of aFGF seems to be suffi-
cient for triggering DNA synthesis, FGFR is indispensable
for other processes of cell proliferation (Wiedlocha et al.,
1994). Consistent with this idea, DNA synthesis was ac-
companied by cell proliferation only in cells which possess
aFGF receptors or if the toxin-resistant cells were trans-
fected with a FGFR (Wiedlocha et al., 1996).
However, one has to keep in mind that cell lines, trans-
fected cells, and tumor cells most probably do not behave
and cannot be considered as normal cells. Nonetheless,
cell proliferation rate and nuclear association of bFGF was
reported to change in parallel not only in glioma cells for
example, which express transfection-derived endogenous
FGF-2, but also in primary cultures of human astrocytes
stimulated with extracellular bFGF (concentration range:
0.09–2.5 nM) (Joy et al., 1997). These observations support
the idea that nuclear translocation of GFs could be related
to mitogenesis in normal, nontransformed cells as well.
Uptake of extracellular bFGF to the nucleus and to the
nucleolus was found to occur only in late G
 
1
 
 phase of the
cell cycle in growing aortic endothelial (ABAE) cells, both
by immunocytochemistry and by analysis of radioiodi-
nated cell fractions (Baldin et al., 1990). Nuclear associa-
tion of FGF-2 was also observed in mid-late G
 
1
 
 phase in
proliferating epiphyseal plate chondrocytes (Kilkenny and
Hill, 1996), suggesting a controlled nuclear entry of GFs
around the restriction point of the cell cycle.
It is important to note that autocrine and intracrine FGF
types can have different effects, which are related to their
partially different sequence and to their characteristic site
of action. From the four different forms of human FGF-2,
the low molecular mass form (with 18 kD) is an autocrine/
paracrine one. The three high molecular mass forms (with
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21–22, 22.5, and 24 kD, respectively) are the intracrine
ones generated by alternative translation initiation at
CUG codon, through an internal ribosome entry process
regulated by a cis-acting mechanism (Vagner et al., 1996).
These intracrine forms, which have a longer, arginine-rich
NH
 
2
 
-terminal with at least two possible short nuclear lo-
calization sequences (NLSs) (Gly-Arg-Gly-Arg-Gly-Arg),
are preferentially targeted to the nucleus (Quarto et al.,
1991). In contrast, the 18-kD form has only a weak or
cryptic short NLS, and is found predominantly in the cyto-
plasm (Quarto et al., 1991; Davis et al., 1997). Only the
short bFGF form can be released from the cell, and can,
therefore, interact with the plasma membrane FGFR. Sur-
prisingly, when intracrine bFGF types were expressed in
NIH 3T3 cells, high proliferation rates and growth in soft
agar were observed, even in the presence of mutant cell
surface bFGF receptors lacking the Tyr kinase domain
(Bikfalvi et al., 1995). This reflects a plasma membrane re-
ceptor–independent pathway, presumably via formation
of complexes between intracrine GFs and intracellular re-
ceptors (see below). In vascular smooth muscle cell lines
expressing different human bFGFs, the intracrine bFGF
forms appeared to be significantly more effective in aug-
menting the rate of DNA synthesis than the autocrine one
(Davis et al., 1997). Moreover, the continuous prolifera-
tion of two glioma cell lines is suggested to be related to
the constitutive presence of endogenous FGF-2 in nuclei;
these cells were nonresponsive to extracellular GFs (Joy
et al., 1997). Synthesis of CUG-initiated forms could be in-
duced also in primary human skin fibroblasts, producing
normally the short bFGF form almost exclusively, by heat
shock (45
 
8
 
C, 15–60 min) and by oxidative stress, which is
probably due to translational activation (Vagner et al.,
1996).
Developmental studies indicated that FGF-2, known as
a maternal signal involved in mesoderm induction in am-
phibians, brings about mesoderm induction via Src-kinase
Laloo (Weinstein et al., 1998) and MAP kinase (Umb-
hauer et al., 1995). However, nuclear bFGF may be in-
volved in other specific developmental phenomena, since
nuclear association of bFGF becomes restricted to some
cell populations during embryogenesis. In the mid-blastula
stage, FGF-2 was demonstrated clearly in the nuclei of the
animal hemisphere of 
 
Xenopus
 
; in the prelarval embryo,
nuclear bFGF was shown in most head regions (including
the brain) and particularly in some muscle cells of the
trunk region (immunocytochemical study by Song and
Slack, 1994). This is consistent with the well-known stimu-
latory effects of bFGF on myoblast proliferation (Burgess
and Maciag, 1989) and on proliferation plus differentiation
of neuroblasts and glial precursor cells (M.K. Stachowiak
et al., 1997). In early chicken embryos, nuclear FGF-2 iso-
forms were observed in most cells of the prestreak blasto-
discs during hypoblast formation and mesoderm induc-
tion. Only the hypoblasts and the blastocoelic cells seemed
to maintain their nuclear immunostaining during primitive
streak formation and with the onset of gastrulation (Riese
et al., 1995). In later phases, only a small proportion of
limb bud cells, most likely migrating myoblasts, and differ-
entiating kidney podocytes were shown to have consider-
able nuclear FGF-2 (immunohistochemical study by Dono
and Zeller, 1994).
 
Nuclear Targeting of GFs and GFRs
 
Recently, several data have accumulated which support
the idea of GF receptor translocation to the nucleus. For
example, three FGFR-1 variants (with 145, 118, and 103 kD,
respectively) were detected in the nucleoplasmic and in
the nuclear matrix fractions of human astrocytes and bo-
vine adrenal medullary cells. In the majority of cells, the
immunofluorescence signals of FGF-2 and FGFR-1 ap-
peared to colocalize in the nuclei (Stachowiak et al.,
1996a,b). So, how could the GFR gain access into the nu-
cleus?
According to the emerging view, NLS-bearing GFs like
FGFs presumably facilitate the nuclear import of their re-
ceptors. Theoretically, GFs do not need NLS to enter the
nucleus, since the molecular “sieves” of nuclear pores de-
mand it only from compounds 
 
.
 
40–45 kD. Possession of
NLSs by low molecular mass GFs implies that this may be
necessary for the nuclear import of their receptors which
can be transported “piggyback” to the nucleus in associa-
tion with NLS-bearing ligands (Jans, 1994; Jans and Has-
san, 1998). The concept that plasma membrane GFRs
could enter the nucleus upon extracellular GF stimulation
is supported by the accurate study of Maher (1996), who
demonstrated a dose- and time-dependent increase of nu-
cleus-associated FGFR-1 immunoreactivity in Swiss 3T3
fibroblasts (onset: within 10 min, max: 1 h; concentration:
5–15–50 ng/ml). Moreover, the FGFR-1 in the nuclear
fraction was shown to bear the impermeable biotin label
of the cell surface proteins and was proven to be of full
length, verifying its plasma membrane origin. Even intra-
crine FGFs may enter the nucleus in complex with intra-
cellular receptors. Consistent with this idea, several trun-
cated forms of FGFR-1 and FGFR-2 have been described,
which are devoid of the transmembrane region (Givol and
Yayon, 1992). Furthermore, a truncated FGFR3 variant
missing the transmembrane part and half of the final Ig-
like domain was shown to be characteristically associated
with cell nuclei in breast epithelial cell lines by immunocy-
tochemistry (Johnston et al., 1995).
Considering the role of high-affinity GF receptors in nu-
clear targeting, they are probably prerequisite for the in-
tracellular transport of GFs to the perinuclear region dur-
ing receptor-mediated endocytosis. According to the
studies of Prudovsky et al. (1996) on transfected L6 myo-
blasts, the first Ig-like loop in type 1 FGFRs may facilitate
the transport of exogenous FGF-1 to the perinuclear area,
as mostly the 
 
a
 
, 3-loop receptor isoforms possessing this
domain (and not the 
 
b
 
 isoforms lacking it) were demon-
strated in the nuclear/perinuclear fraction. N-glycosylation
seems to be also important, as tunicamycin treatment sig-
nificantly reduced the presence of the 
 
a
 
 receptor forms in
the nuclear/perinuclear fraction. This can be interpreted
on the basis of NLS-independent, but sugar-dependent nu-
clear import mechanism described by Duverger et al.
(1995), as GFRs are glycoproteins (M.K. Stachowiak et al.,
1997).
Regarding FGFs, possible involvement of low-affinity
saccharide receptors in nuclear translocation cannot be
ruled out. Heparan sulfate proteoglycans (HSPGs) with
highly O-sulfated oligosaccharide chains are well known
to play a crucial role in the formation and in the mainte- 
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nance of the active FGFR–a/bFGF complexes at the
plasma membrane (Luo et al., 1996). Perlecan, a basal
lamina proteoglycan (Aviezer et al., 1994), syndicans, and
glypican (Steinfeld et al., 1996) proved to be effective in
stimulating FGF–FGFR interaction. It is thought that
HSPG and extracellular bFGF bound to FGFR might be
cotranslocated to the nucleus; HSPG could stabilize the
complex and protect it from degradation in the endocy-
totic vesicles and in the lysosomes (Reiland and Raprae-
ger, 1993). Since glypican was observed in association with
cell nuclei (in rat neurons and in glioma cells) and, more-
over, it was shown to have functional NLS (Liang et al.,
1997), this gives further credence to the mentioned idea.
In NIH 3T3 cells, the constitutively activated FGFR-3
mutant kinase domains in linkage with the plasma mem-
brane appeared to be sufficient to trigger cell proliferation
and transformation, in contrast to wild-type kinase do-
mains, or to activated kinase domains targeted to the nu-
cleus or to the cytoplasm (Webster and Donoghue, 1997).
However, in astrocyte and glioma cultures, cell prolifera-
tion appeared to correlate with the nuclear presence of
FGFR-1. Continuously proliferating glioma cells, unre-
sponsive to external FGF, displayed constitutive nuclear
association of FGFR-1. In contrast, astrocytes had de-
creasing nuclear appearance of FGFR-1 in parallel to in-
creasing cell density in cultures approaching confluency.
Furthermore, enhanced cell proliferation rate could be
achieved in glioma cells lacking FGFR-1 by transfecting
them with the full-length receptor cDNA; thereafter, im-
munoreactivity of FGFR-1 was seen predominantly in as-
sociation with the nucleus (E.K. Stachowiak et al., 1997).
Both in astrocytes and in bovine adrenal medullary cells,
the nuclear FGFR was shown to retain kinase activity.
With this observation, we arrived at a basic, but currently
unresolved question.
How could GFs and GFRs act in the nucleus? Nuclear
FGFR kinase activity is thought to have no significant role
in the induction of cell proliferation (Webster and Dono-
ghue, 1997). However, bFGF may be involved in induction
of ribosomal gene transcription via stimulation of casein
kinase-2, which is known to regulate nucleolin, a major
component of the nucleolus implicated in ribosome bio-
genesis. Using nuclear extracts of FM3A cells and purified
proteins, FGF-2 was shown to bind CK-2 and stimulate
its activity, resulting in an increased phosphorylation of
nucleolin (Bonnet et al., 1996). (Enhancement of CK-2
activity reached its maximum at 10
 
-7
 
 M FGF-2 concentra-
tion, which was calculated to be a possible bFGF concen-
tration in the nucleus.) Supporting these observations,
rRNA was found to increase severalfold upon addition of
bFGF (0.1–1 nM) to isolated nuclei from quiescent ABAE
cells (Bouche et al., 1987). Furthermore, GF–GFR com-
plexes may cotransport intranuclearly acting molecules to
the nucleus, via binding to the receptor, as was suggested
for IFN-
 
g
 
–IFN receptor complex and STAT by Johnson
et al. (1998).
 
Normal Cells: Anchorage-dependent GF Transport to 
the Nucleus?
 
According to the classic view, extracellular GFs stimulate
their receptor-mediated endocytosis, which leads to degra-
dation (or to recycling) of GF receptors. However, it is
plausible to suppose that a portion of GFs and GFRs can
escape from the endosomes or lysosomes and may reach
the nucleus. Growth hormone was demonstrated to un-
dergo a receptor-dependent nuclear translocation via the
endosomes in rat hepatocytes (Lobie et al., 1994; electron
microscopic autoradiography); its nuclear uptake could be
significantly increased upon the addition of some lyso-
some inhibitors, indicating an escape route from the ly-
sosomes. It is noteworthy that FGFR-1 could be detected
only in few regions at the nuclear envelope and displayed
a patchy distribution within the nucleus of bovine adrenal
medullary cells; this may reflect nuclear entry at deter-
mined membrane pores and controlled transport to special
nuclear sites (immunoelectron microscopy by Stachowiak
et al., 1996b).
It is intriguing to hypothesize that actin is involved not
only in endocytosis and in the transport of endosomes to
the perinuclear area (Durrbach et al., 1996), but also in the
precise nuclear targeting of GF–GFR complexes from the
perinuclear cytoplasm, since actin is known to be present
in abundance in cell nuclei, both in the chromatin and in
the nuclear matrix fraction (Capco et al., 1982). Further-
more, there is evidence that a GF receptor, the EGFR, is a
(direct) actin-binding protein (den Hartigh et al., 1992);
other GFRs may be linked to actin indirectly, via actin-
binding proteins, during their nuclear translocation.
It should be noted in this context that extracellular
matrix-dependent cytoskeletal organization supervises
GF action on proliferation of normal cells, reflected in
the well-known phenomenon of anchorage-dependent
growth. Cell division is generally preceded by extensive
cell spreading (Alberts et al., 1994). Spreading is probably
necessary for nuclear translocation of GF–GFR complex
in normal cells, since only astrocytes in subconfluent cul-
tures (and not the ones in confluent cultures in short of ex-
tracellular surface) were observed to have nuclear-associ-
ated bFGF and FGFR-1. On the contrary, in continuously
growing glioma cells, nuclear appearance of FGF-2 and
FGFR-1 was constitutive and was largely independent of
cell density (Joy et al., 1997; E.K. Stachowiak et al., 1997).
Finally, bFGF gene is continuously activated in glioma
cells irrespective of cell density, whereas in astrocytes
bFGF transcription is induced by subconfluency (Moffett
et al., 1996).
All in all, it seems that a portion of internalized exoge-
nous FGFs plus their receptors may escape degradation
and could be transported to the cell nucleus. Nuclear GF–
GFR complexes appear to stimulate cell proliferation in
certain conditions in several cell types; in addition, activa-
tion of cell line–specific genes may occur in some differen-
tiating cells. Continuous proliferation of transformed cells
could be partially due to the continuous nuclear presence
of GFs and GFRs. Obviously, much work has to be done
to elucidate details of the nuclear targeting of GF–GFR
complexes and to be able to understand their nuclear ac-
tion fully.
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